The phrase "agents for evaluation" is correct and usable in written English.
It can be used in contexts where you are referring to individuals or entities that are responsible for assessing or analyzing something.
Example: "The company hired external agents for evaluation to ensure an unbiased review of their performance metrics."
Alternatives: "evaluators" or "assessment agents".
"We do however, select agents for evaluation through our programs... that we feel warrant regulatory agency consideration".
In this presentation, MR imaging protocols and use of gadolinium, iron and manganese based MR contrast agents for evaluation of suspected or known liver metastases are discussed.
Gadolinium-based contrast agents (GBCAs), currently the only FDA-approved contrast agents for evaluation of the breast, received FDA clearance in 1988.
Nowadays, 99mTc-DTPA is a well-known agent for evaluation of renal function.
The Monograph Programme convenes meetings of special Advisory Groups (composed of external scientists that possess a broad range of relevant professional skills) to review agents nominated for evaluation and to suggest IARC priorities for such reviews (Ward et al. 2010).
Since the opinion recommends additional screening of drugs for potential efficacy, how will (should) decisions be made to select specific agents for further evaluation or clinical use?
Although non-contrast T1-weighted and T2-weighted imaging, together with low molecular weight extracellular gadolinium contrast-enhanced T1-weighted MR imaging remain the cornerstone for liver assessment, there is increasing recognition of the benefits of liver-specific contrast agents for disease evaluation.
Although non-contrast T1-weighted and T2-weighted imaging, together with low molecular weight extracellular gadolinium contrast-enhanced T1-weighted magnetic resonance imaging remain the cornerstone for liver assessment, there is increasing recognition of the benefits of liver-specific contrast agents for disease evaluation.
Agents are selected for evaluation based on evidence of human exposure and some evidence or suspicion of carcinogenicity.
Although additional GLP-1 receptor agonists (liraglutide and exenatide once weekly) have since been approved by the European Commission, exenatide BID and insulins were the only injectable treatments available when this study commenced, hence these agents were selected for evaluation.
To evaluate two novel therapies for resistant FSGS - adalimumab, a human anti-TNF-α antibody, and galactose - compared to standard conservative therapy; 2. To identify one or more novel agents as candidates for evaluation in a future Phase III RCT; and 3. To create and sustain an infrastructure for the timely completion of RCTs in patients with rare glomerular diseases like primary FSGS.
